Serum markers to monitor response to zoledronic acid in patients with bone metastases from breast cancer.

被引：0
|
作者：
Mercatali, L.
Ibrahim, T.
Sacanna, E.
Ricci, R.
Scarpi, E.
Fabbri, F.
Serra, P.
Tison, C.
Amadori, D.
机构：
[1] Osteooncol Ctr, Meldola, Italy
[2] IRST, Meldola, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1105
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effects of zoledronic acid on serum levels of MMPs and bone remodeling markers in breast cancer patients with bone metastases
    Kanakis, I
    Nikolaou, M
    Kiamouris, C
    Pectasides, D
    Karamanos, N
    [J]. FEBS JOURNAL, 2005, 272 : 270 - 270
  • [2] Zoledronic acid for the prevention of bone metastases in patients with breast cancer
    Coleman, R.
    Gralow, J.
    Bell, R.
    Lipton, A.
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 74 - 75
  • [3] Zoledronic acid and survival in breast cancer patients with bone Metastases and elevated markers of osteoclast activity
    Lipton, Allan
    Cook, Richard J.
    Major, Pierre
    Smith, Matthew R.
    Coleman, Robert E.
    [J]. ONCOLOGIST, 2007, 12 (09): : 1035 - 1043
  • [4] Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases
    Generali, D.
    Dovio, A.
    Tampellini, M.
    Tucci, M.
    Tedoldi, S.
    Torta, M.
    Bonardi, S.
    Allevi, G.
    Aguggini, S.
    Milani, M.
    Harris, A. L.
    Bottini, A.
    Dogliotti, L.
    Angeli, A.
    Berruti, A.
    [J]. BRITISH JOURNAL OF CANCER, 2008, 98 (11) : 1753 - 1758
  • [5] Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases
    D Generali
    A Dovio
    M Tampellini
    M Tucci
    S Tedoldi
    M Torta
    S Bonardi
    G Allevi
    S Aguggini
    M Milani
    A L Harris
    A Bottini
    L Dogliotti
    A Angeli
    A Berruti
    [J]. British Journal of Cancer, 2008, 98 : 1753 - 1758
  • [6] Breast cancer bone metastases: denosumab or zoledronic acid?
    Gabri van der Pluijm
    [J]. Nature Reviews Endocrinology, 2011, 7 : 134 - 135
  • [7] Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
    Hilton, J. F.
    Clemons, M.
    Pond, G.
    Zhao, H.
    Mazzarello, S.
    Vandermeer, L.
    Addison, C. L.
    [J]. JOURNAL OF BONE ONCOLOGY, 2018, 10 : 6 - 13
  • [8] Survival in breast cancer patients with bone metastases and reductions in markers of bone resorption during zoledronic acid treatment.
    Lipton A
    Cook R
    Major P
    Smith M
    Coleman R
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S39 - S39
  • [9] CANCER Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm, Gabri
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (03) : 134 - 135
  • [10] Association of 13 serum biochemical markers with bone metastases in women with breast cancer.
    Voorzanger-Rousselot, N
    Juillet, F
    Zimmermann, J
    Cretet, V
    Mareau, E
    Kalebic, T
    Garnero, P
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S224 - S224
12345